STOCKHOLM, SWEDEN – April 17, 2023. Karolinska Development AB today announces that its portfolio company Umecrine Cognition has included the first patient in a Phase 2 clinical trial of the. | April 17, 2023
STOCKHOLM, SWEDEN April 13, 2023. Karolinska Development AB today announces that its portfolio company AnaCardio has included the first patient in the company’s clinical phase 1b/2a study of. | April 13, 2023
The shareholders of Karolinska Development AB , reg. no. 556707-5048, are invited to the Annual General Meeting, on Tuesday May 16, 2023, at 3:00 p.m. , at Life City, Solnavägen 3, SE-113. | April 11, 2023
STOCKHOLM, SWEDEN – March 28, 2023. Karolinska Development AB today announces that the portfolio company Umecrine Cognition has secured additional funding for the continued development of the. | March 28, 2023
STOCKHOLM, SWEDEN – March 24, 2023. Karolinska Development AB today announces publication of its Annual Report 2022. The report is now available to download at www.karolinskadevelopment.com . | March 24, 2023